

## Clinical Oversight Review Board (CORB) Criteria for Prescribing

# Ocrelizumab and hyaluronidase (Ocrevus Zunovo)

### Notes:

- Quantity Limits: No
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **ocrelizumab and hyaluronidase (Ocrevus Zunovo)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

**Initiation (new start) criteria, criteria for *current Kaiser Permanente members* already taking the medication who have not been reviewed previously, and criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously:**

- Prescribed by a Neurologist
- Patient has a diagnosis of Multiple Sclerosis
- Patient has tried an infusion of rituximab or a rituximab biosimilar product, and experienced an allergic reaction